Skip to main content
STTK
NASDAQ Life Sciences

Shattuck Labs Prices $75M Public Offering at $4/Share, Significant Dilution Expected

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.17
Mkt Cap
$327.426M
52W Low
$0.712
52W High
$8.33
52W Position info
486% above low
Off High info
50% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

STTK has more than doubled off its 52-week low of $0.712 on elevated volume (2.3× avg).

Summary

Shattuck Labs has priced its public offering, raising $75 million by selling 10.88 million shares at $4.00 each. This follows yesterday's announcement of the offering's commencement and recent news of positive Phase 1 clinical trial results and a $54.9 million cash infusion from warrant exercises. The offering is highly dilutive, representing approximately 23% of the company's current market capitalization, and is priced below the current market price. While it bolsters the company's cash position, the terms are unfavorable for existing shareholders.

At the time of this announcement, STTK was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $327.4M. The 52-week trading range was $0.71 to $8.33. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

STTK - Latest Insights

STTK
Nov 05, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
7
STTK
Nov 05, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
STTK
Oct 01, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
7
STTK
Aug 11, 2026, 6:59 AM EDT
Filing Type: 8-K
Importance Score:
7
STTK
Aug 11, 2026, 6:57 AM EDT
Filing Type: 10-Q
Importance Score:
7